Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Overweight rating on the shares. Palvella announced QTORIN pitavastatin for disseminated superficial actinic porokeratosis, the analyst tells investors in a research note. It appears the Palvella team has found the key to unlocking multiple rare derm conditions in a low-risk/high-reward way, the firm says.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $190 from $95 at H.C. Wainwright
- Buy Rating for Palvella Therapeutics: Innovative Approach and Strategic Development in Rare Dermatological Treatments
- Strategic Expansion of Palvella Therapeutics’ QTORIN Platform Targets Unmet Needs in Rare Skin Conditions
- Palvella Therapeutics price target raised to $87 from $80 at Stifel
- Palvella price target raised to $200 from $120 at Cantor Fitzgerald